What's in Hanmi Pharmaceutical Company Limited's pipeline?

Hanmi Pharmaceutical Company Limited has 169 drugs in our index: 14 marketed, 0 filed, 66 in Phase 3, 14 in Phase 2, 75 in Phase 1.

Which companies overlap with Hanmi Pharmaceutical Company Limited's portfolio?

Top competitors by shared drug class: AstraZeneca, Daewoong Pharmaceutical Co. LTD., Sanofi, Novo Nordisk A/S, Astellas Pharma Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hanmi-pharmaceutical-company-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Hanmi Pharmaceutical Company Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hanmi Pharmaceutical Company Limited pipeline: 14 marketed, 0 filed, 66 Phase 3, 14 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

14 marketed 0 filed 66 Phase 3 14 Phase 2 75 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Atorvastatin A	Atorvastatin A	marketed
Rosuvastatin and Ezetimibe	Rosuvastatin and Ezetimibe	marketed	Statin and ezetimibe combination	HMG-CoA reductase and NPC1L1 transporter	Cardiovascular
current treatment	current treatment	marketed
two-way education	two-way education	marketed
Simvast CR	Simvast CR	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	Cardiovascular
Victoza	Victoza	marketed		Glucagon-like peptide 1 receptor	Metabolic
one-way education	one-way education	marketed
Atorvastatin B	Atorvastatin B	marketed
Cavir	Cavir	marketed			Other
Amlodipine, Losartan	Amlodipine, Losartan	marketed
Zocor	Zocor	marketed			Other
Amosartan® tab	Amosartan® tab	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)	Cardiovascular

Therapeutic area mix

Diabetes · 29
Oncology · 14
Cardiovascular · 8
Endocrinology / Diabetes · 7
Endocrinology · 4
Other · 3
Endocrinology / Metabolic Disease · 1
Allergy/Immunology · 1
Immunology / Allergy · 1
Metabolic · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 6 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 5 shared drug classes
Sanofi · 5 shared drug classes
Novo Nordisk A/S · 4 shared drug classes
Astellas Pharma Inc · 4 shared drug classes
Bayer · 4 shared drug classes
Chong Kun Dang Pharmaceutical · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Hanmi Pharmaceutical Company Limited:

Cite this brief

Drug Landscape (2026). Hanmi Pharmaceutical Company Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hanmi-pharmaceutical-company-limited. Accessed 2026-05-16.